GW rises after latest Epidiolex readout

GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) said anticonvulsive therapy Epidiolex cannabidiol met the primary endpoint of a Phase III study to treat Lennox-Gastaut syndrome (LGS). In June, Epidiolex met the primary endpoint in another Phase III trial in the same indication (see BioCentury Extra, June 27).

On Monday, GW gained 91p (13%) to 790p in London and rose $18.50 (17%) to $126.06 on NASDAQ. ...